153 related articles for article (PubMed ID: 9646285)
1. Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.
Nishimura T; Takeda M; Nakamura Y; Yosbida Y; Arai H; Sasaki H; Shouji M; Hirai S; Khise K; Tanaka K; Hamamoto M; Yamamoto H; Matsubayashi T; Urakami K; Adachi Y; Nakashima K; Toji H; Nakamura S; Yoshida H
Methods Find Exp Clin Pharmacol; 1998 Apr; 20(3):227-35. PubMed ID: 9646285
[TBL] [Abstract][Full Text] [Related]
2. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease].
Urakami K; Ito N; Arai H; Ishiguro K; Ohno H; Nakashima K
Seishin Shinkeigaku Zasshi; 2003; 105(4):393-7. PubMed ID: 12806900
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of tau in cerebrospinal fluid in alzheimer disease].
Hu Y; He S; Wang J
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1377-9. PubMed ID: 11930632
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.
Kanai M; Matsubara E; Isoe K; Urakami K; Nakashima K; Arai H; Sasaki H; Abe K; Iwatsubo T; Kosaka T; Watanabe M; Tomidokoro Y; Shizuka M; Mizushima K; Nakamura T; Igeta Y; Ikeda Y; Amari M; Kawarabayashi T; Ishiguro K; Harigaya Y; Wakabayashi K; Okamoto K; Hirai S; Shoji M
Ann Neurol; 1998 Jul; 44(1):17-26. PubMed ID: 9667589
[TBL] [Abstract][Full Text] [Related]
5. Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
Leszek J; Małyszczak K; Janicka B; Kiejna A; Wiak A
Med Sci Monit; 2003 Nov; 9(11):CR484-8. PubMed ID: 14586274
[TBL] [Abstract][Full Text] [Related]
6. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.
Arai H; Terajima M; Miura M; Higuchi S; Muramatsu T; Machida N; Seiki H; Takase S; Clark CM; Lee VM
Ann Neurol; 1995 Oct; 38(4):649-52. PubMed ID: 7574462
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia.
Jia JP; Meng R; Sun YX; Sun WJ; Ji XM; Jia LF
Neurosci Lett; 2005 Jul 22-29; 383(1-2):12-6. PubMed ID: 15936505
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid markers in differential diagnosis of Alzheimer's disease and vascular dementia.
Boban M; Grbić K; Mladinov M; Hof PR; Süssmair C; Ackl N; Stanić G; Bader B; Danek A; Simić G
Coll Antropol; 2008 Jan; 32 Suppl 1():31-6. PubMed ID: 18405055
[TBL] [Abstract][Full Text] [Related]
9. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.
Galasko D
J Neural Transm Suppl; 1998; 53():209-21. PubMed ID: 9700659
[TBL] [Abstract][Full Text] [Related]
11. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.
Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G
Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339
[TBL] [Abstract][Full Text] [Related]
13. Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.
Munroe WA; Southwick PC; Chang L; Scharre DW; Echols CL; Fu PC; Whaley JM; Wolfert RL
Ann Clin Lab Sci; 1995; 25(3):207-17. PubMed ID: 7605102
[TBL] [Abstract][Full Text] [Related]
14. MRI and CSF studies in the early diagnosis of Alzheimer's disease.
de Leon MJ; DeSanti S; Zinkowski R; Mehta PD; Pratico D; Segal S; Clark C; Kerkman D; DeBernardis J; Li J; Lair L; Reisberg B; Tsui W; Rusinek H
J Intern Med; 2004 Sep; 256(3):205-23. PubMed ID: 15324364
[TBL] [Abstract][Full Text] [Related]
15. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
16. [Cerebrospinal fluid protein tau levels in the differential diagnosis of Alzheimer's disease].
Schonknecht P; Pantel J; Werle E; Hartmann T; Essig M; Baudendistel K; Beyreuther K; Schroder J
Fortschr Neurol Psychiatr; 2000 Oct; 68(10):439-46. PubMed ID: 11103680
[TBL] [Abstract][Full Text] [Related]
17. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
18. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.
Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J
Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of tau protein, beta-amyloid (1-42) and their ratio for the discrimination of alcohol-related cognitive disorders from Alzheimer's disease in the early stages.
Kapaki E; Liappas I; Paraskevas GP; Theotoka I; Rabavilas A
Int J Geriatr Psychiatry; 2005 Aug; 20(8):722-9. PubMed ID: 16035118
[TBL] [Abstract][Full Text] [Related]
20. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]